Evidence map›Paper›PMID 21256666›Full record

ArticleUltrasound in medicine & biology2011

Gene therapy of carcinoma using ultrasound-targeted microbubble destruction.

Andrew R Carson, Charles F McTiernan, Linda Lavery, Abigail Hodnick, Michelle Grata, Xiaoping Leng, Jianjun Wang, Xucai Chen, Ruth A Modzelewski, Flordeliza S Villanueva

Open access · greenAbstract read
In one paragraph

Article in Ultrasound in medicine & biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 93 citations in OpenAlex.

  1. Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma.Methods in molecular biology (Clifton, N.J.) · 2020
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Sonoselective transfection of cerebral vasculature without blood-brain barrier disruption.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2018
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andrew R CarsonCenter for Ultrasound Molecular Imaging and Therapeutics, Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Charles F McTiernan
Linda Lavery
Abigail Hodnick
Michelle Grata
Xiaoping Leng
Jianjun Wang
Xucai Chen
Ruth A Modzelewski
Flordeliza S Villanueva
University of Pittsburgh Medical Center · USUPMC Hillman Cancer Center · US

Funding

WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6M
Ultrasound-activated microbubbles for targeted siRNA delivery to tumorR01EB016516 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VILLANUEVA, FLORDELIZA S · 2012 to 2015
$2.3M
Targeted Ultrasound Imaging of Angiogenic ReceptorsR01HL077534 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VILLANUEVA, FLORDELIZA S · 2004 to 2007
$1.4M
NCI NIH HHS P50 CA097190NHLBI NIH HHS R01 HL077534NHLBI NIH HHS R01HL077534-01NIBIB NIH HHS R01 EB016516
6 · The paper itself

Abstract

When microbubble contrast agents are loaded with genes and systemically injected, ultrasound-targeted microbubble destruction (UTMD) facilitates focused delivery of genes to target tissues. A mouse model of squamous cell carcinoma was used to test the hypothesis that UTMD would specifically transduce tumor tissue and slow tumor growth when treated with herpes simplex virus thymidine kinase (TK) and ganciclovir. UTMD-mediated delivery of reporter genes resulted in tumor expression of luciferase and green fluorescent protein (GFP) in perivascular areas and individual tumor cells that exceeded expression in control tumors (p=0.02). The doubling time of TK-treated tumors was longer than GFP-treated tumors (p=0.02), and TK-treated tumors displayed increased apoptosis (p=0.04) and more areas of cellular drop-out (p=0.03). These data indicate that UTMD gene therapy can transduce solid tumors and mediate a therapeutic effect. UTMD is a promising nonviral method for targeting gene therapy that may be useful in a spectrum of tumors.

Indexed as

SonicationAnimalsCarcinoma, Squamous CellGenetic TherapyMiceMice, Inbred C3HMicrospheresThymidine KinaseTransfectionTreatment OutcomeThymidine Kinase

Identifiers

PMID21256666
PMCPMC4111473
OpenAlexW2100207346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.